Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM.

Lancet Neurol. 2006 Aug;5(8):655-60.

PMID:
16857570
2.

Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.

Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alpérovitch A, Buée L, Amouyel P.

Neurology. 2009 Sep 15;73(11):847-53. doi: 10.1212/WNL.0b013e3181b78448.

PMID:
19752451
3.

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.

Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I.

J Alzheimers Dis. 2012;28(1):231-8. doi: 10.3233/JAD-2011-111418.

PMID:
21955816
4.

Plasma amyloid β, depression, and dementia in community-dwelling elderly.

Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman A, Ikram MA, Tiemeier H.

J Psychiatr Res. 2013 Apr;47(4):479-85. doi: 10.1016/j.jpsychires.2012.12.008. Epub 2013 Jan 11.

5.

The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.

J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.

PMID:
21440911
6.

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L.

Arch Neurol. 2008 Feb;65(2):256-63. doi: 10.1001/archneurol.2007.57.

PMID:
18268197
7.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2010;21(1):291-301. doi: 10.3233/JAD-2010-091501.

PMID:
20421698
8.

Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.

Coppus AM, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM, van Duijn CM.

Neurobiol Aging. 2012 Sep;33(9):1988-94. doi: 10.1016/j.neurobiolaging.2011.08.007. Epub 2011 Sep 29.

9.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
10.

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, Wolf PA, Younkin S, Seshadri S.

Alzheimers Dement. 2015 Mar;11(3):249-57.e1. doi: 10.1016/j.jalz.2014.07.001. Epub 2014 Sep 10.

11.

Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W.

Neurology. 2010 Nov 2;75(18):1639-44. doi: 10.1212/WNL.0b013e3181fb448b.

12.

Plasma biomarkers of Alzheimer's disease.

Kawarabayashi T, Shoji M.

Curr Opin Psychiatry. 2008 May;21(3):260-7. doi: 10.1097/YCO.0b013e3282fc989f. Review.

PMID:
18382225
13.

Plasma beta amyloid level and depression in older adults.

Metti AL, Cauley JA, Newman AB, Ayonayon HN, Barry LC, Kuller LM, Satterfield S, Simonsick EM, Yaffe K.

J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):74-9. doi: 10.1093/gerona/gls093. Epub 2012 Apr 12.

14.

Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.

Kitaguchi N, Kawaguchi K, Nakai S, Murakami K, Ito S, Hoshino H, Hori H, Ohashi A, Shimano Y, Suzuki N, Yuzawa Y, Mutoh T, Sugiyama S.

Blood Purif. 2011;32(1):57-62. doi: 10.1159/000322624. Epub 2011 Feb 24.

PMID:
21346337
15.

Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.

Tzikas S, Schlak D, Sopova K, Gatsiou A, Stakos D, Stamatelopoulos K, Stellos K, Laske C.

J Alzheimers Dis. 2014;39(3):557-64. doi: 10.3233/JAD-131469.

PMID:
24217274
16.

Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study.

Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buée L, Dartigues JF, Touchon J, Lambert JC, Berr C.

J Alzheimers Dis. 2013;33(2):381-91. doi: 10.3233/JAD-2012-121147.

17.

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K.

Neurobiol Aging. 2010 Mar;31(3):357-67. doi: 10.1016/j.neurobiolaging.2008.03.027. Epub 2008 May 19.

PMID:
18486992
18.

Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT.

J Alzheimers Dis. 2011;23(3):399-409. doi: 10.3233/JAD-2010-101335.

19.

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F.

Arch Neurol. 2012 Jul;69(7):824-31. Review.

20.

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.

Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.

PMID:
23477989

Supplemental Content

Support Center